Suppr超能文献

拉米夫定治疗后乙型肝炎所致失代偿性肝病患者的临床改善情况。

Clinical improvement in patients with decompensated liver disease caused by hepatitis B after treatment with lamivudine.

作者信息

Sponseller C A, Bacon B R, Di Bisceglie A M

机构信息

Department of Internal Medicine, Division of Gastroenterology and Hepatology, Saint Louis University School of Medicine, St Louis, MO 63104, USA.

出版信息

Liver Transpl. 2000 Nov;6(6):715-20. doi: 10.1053/jlts.2000.18501.

Abstract

Lamivudine is effective in inhibiting hepatitis B virus (HBV) replication, and its clinical use in patients with chronic hepatitis B is associated with improvements in serum aminotransferase levels and liver histopathologic characteristics. Few data are available on its use in patients with advanced liver disease. We report on the outcomes of 5 patients with hepatic decompensation caused by chronic hepatitis B treated long term with lamivudine. All patients were adult white men seropositive for hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) before therapy. All 5 patients had biopsy-proven cirrhosis with clinical and biochemical evidence of hepatic decompensation. Two patients had Child's class C cirrhosis; 2 patients, class B; and 1 patient, class A (although this patient had persistent portasystemic encephalopathy and developed variceal bleeding). HBV DNA became undetectable in all patients and remained so throughout the study. Both patients with Child's class C and 1 patient with class B cirrhosis had significant clinical improvement. Child-Pugh scores improved from 12 to 7 and 11 to 7 in the 2 patients with Child's class C cirrhosis, and the patient with class B cirrhosis had complete resolution of troublesome encephalopathy. Serum aminotransferase, albumin, and total bilirubin levels improved significantly in 3 of 5 patients. One patient with Child's class B cirrhosis underwent orthotopic liver transplantation at week 13 after dramatic increases in liver tests and clinical worsening. The patient subsequently cleared HBeAg and HBsAg from serum posttransplantation. In conclusion, prolonged therapy with lamivudine resulted in improved serum biochemical values and loss of HBV DNA in patients with decompensated cirrhosis. Clinical improvements, reflected in Child-Pugh classification and functional status, may also occur, particularly among those with Child's class C disease initially.

摘要

拉米夫定可有效抑制乙型肝炎病毒(HBV)复制,其在慢性乙型肝炎患者中的临床应用与血清转氨酶水平改善及肝脏组织病理学特征改善相关。关于其在晚期肝病患者中的应用数据较少。我们报告了5例因慢性乙型肝炎导致肝失代偿的患者长期接受拉米夫定治疗的结果。所有患者在治疗前均为成年白人男性,乙肝表面抗原(HBsAg)和乙肝e抗原(HBeAg)血清学阳性。所有5例患者均经活检证实为肝硬化,并有肝失代偿的临床和生化证据。2例患者为Child C级肝硬化;2例为B级;1例为A级(尽管该患者持续性门体性脑病并发生静脉曲张出血)。所有患者的HBV DNA均变为不可检测,并在整个研究过程中保持如此。2例Child C级肝硬化患者和1例B级肝硬化患者有显著的临床改善。2例Child C级肝硬化患者的Child-Pugh评分从12分改善至7分,从11分改善至7分,B级肝硬化患者的顽固性脑病完全缓解。5例患者中有3例血清转氨酶、白蛋白和总胆红素水平显著改善。1例Child B级肝硬化患者在肝酶急剧升高和临床恶化后第13周接受了原位肝移植。该患者随后在移植后血清中清除了HBeAg和HBsAg。总之,拉米夫定长期治疗可使失代偿性肝硬化患者的血清生化指标改善,HBV DNA消失。Child-Pugh分类和功能状态所反映的临床改善也可能出现,尤其是最初为Child C级疾病的患者。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验